Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NRG Therapeutics

Request full access

Mitochondrial therapeutics for neurodegenerative diseases

Cambridge, United KingdomFounded 2018Biotech & Life Sciences

About NRG Therapeutics

NRG Therapeutics is a drug discovery company founded in 2018, developing treatments for neurodegenerative disorders like Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). The company's scientific focus is on restoring mitochondrial function by developing small molecule inhibitors of the mitochondrial permeability transition pore (mPTP). Inhibition of the mPTP has been demonstrated in pre-clinical models to protect neurons, decrease neuroinflammation, and improve survival.

The company was co-founded by Neil D. Miller, Richard Rutter, and Grant Hawthorne. Dr. Miller, the CEO, has an extensive background in drug discovery, including an 18-year career at GlaxoSmithKline where he led teams that developed multiple clinical candidates. The founders and leadership team are composed of professionals with significant experience in biotech and pharmaceuticals, specifically within neuroscience research and development.

NRG Therapeutics operates on a business model centered on the discovery and development of its drug candidates, with a goal of advancing them to clinical trials. Its pipeline includes brain-penetrant, oral small molecule inhibitors. The company's lead development candidate, NRG5051, is a first-in-class mPTP inhibitor with potential applications for Parkinson's and ALS.

The company is privately held and based at the Stevenage Bioscience Catalyst in the UK. It has successfully raised capital through a combination of equity investments and grants. Key investors include Omega Funds, Brandon Capital, and Parkinson's UK's Virtual Biotech program. NRG has also secured significant grant funding from organizations such as The Michael J. Fox Foundation, Innovate UK, and Target ALS. Total funding has reached over $18.4 million across several rounds, including a Series A round and multiple grants.

Source: Dealroom company data

At a glance

Status
Operational
Employees
23
Open positions
None listed
Dealroom signal
91.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Feb 2026 $26M $330M Undisclosed ↗
SERIES BOther financing Sep 2025 $66M $264M Omega Funds · Brandon Capital Partners · Novartis Venture Fund · British Business Bank ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

NRG Therapeutics website traffic

Latest recorded traffic for NRG Therapeutics is 2.2K monthly website visits, up 29.4% over the last three months. NRG Therapeutics's team grew 21.1% over the past year.

Latest monthly visits2.2K 3-month web change+29.4% 1-year team growth+21.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NRG Therapeutics in the Cambridge ecosystem

Live from Dealroom

The NRG Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Parkinson's UK
  • Michael J. Fox Foundation for Parkinson's Research
  • Target ALS

Series A7 investors entered at this stage

  • Omega Funds
  • Brandon Capital Partners
  • SV Health Investors
  • Novartis Venture Fund
  • British Business Bank
  • M Ventures
  • Criteria Bio Ventures
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇬🇧 United Kingdom70.6%
🇳🇱 Netherlands11.8%
🇪🇸 Spain5.9%
🇦🇺 Australia5.9%
🇺🇸 United States5.9%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NRG Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NRG Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.